Tomioka Shinichiro, Ishigooka Jun
Seishin Shinkeigaku Zasshi. 2006;108(6):614-8.
In Japan, antipsychotic polypharmacy with high doses for schizophrenia has been traditionally used. However, antipsychotic polyphamacy with high doses provide disadvantages for patient. Recent PET studies show that dopamine D2 occupancy with antipsychotics is important for the treatment of schizophrenia. First, antipsychotics become effective only at which their D2 occupancy exceeds 65%. Second, antipsychotics with D2 occupancy below 90% rarely causes occupancy exceeds 65%. Second, antipsychotics with D2 occupancy below 90% rarely causes extrapyramidal side effect. These results suggest that monopharmacy which uses a single antipsychotic agent with appropriate dose is recommended for schizophrenia treatment.
在日本，传统上一直采用高剂量抗精神病药物联合治疗精神分裂症。然而，高剂量抗精神病药物联合治疗对患者存在不利之处。最近的正电子发射断层扫描（PET）研究表明，抗精神病药物的多巴胺D2受体占有率对精神分裂症的治疗很重要。首先，抗精神病药物只有在其D2受体占有率超过65%时才会起效。其次，D2受体占有率低于90%的抗精神病药物很少会使受体占有率超过65%。其次，D2受体占有率低于90%的抗精神病药物很少引起锥体外系副作用。这些结果表明，对于精神分裂症的治疗，推荐使用单一抗精神病药物并给予适当剂量的单药治疗。
